SCHEMBL2127652

SCHEMBL2127652

COc1c(/C=C(\C)c2ccc(NS(C)(=O)=O)cc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.74
CRBN Q96SW2 1/20 0.37
PDPK1 O15530 1/20 0.33
ABL1 P00519 1/20 0.33
CDK9 P50750 1/20 0.32
WDR5 P61964 1/20 0.32
EPHX2 P34913 1/20 0.32
NR1H4 Q96RI1 1/20 0.32
HPGD P15428 2/20 0.32
MAPK10 P53779 1/20 0.32
PTGS2 P35354 1/20 0.31
JAK2 O60674 1/20 0.31
JAK1 P23458 1/20 0.31
TYK2 P29597 1/20 0.31
JAK3 P52333 1/20 0.31
PIP4K2A P48426 1/20 0.31
PIP4K2B P78356 1/20 0.31
PIP4K2C Q8TBX8 1/20 0.31
NR3C2 P08235 1/20 0.31
ALPL P05186 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2127662 1.00 CYP3A4 (0.74) CYP3A4CRBNPDPK1ABL1CDK9
SCHEMBL2127657 1.00 CYP3A4 (0.74) CYP3A4CRBNPDPK1ABL1CDK9
SCHEMBL1542865 0.90 CYP3A4 (0.72) CYP3A4CRBNPDPK1ABL1CDK9
SCHEMBL2128534 0.90 CYP3A4 (0.72) CYP3A4CRBNPDPK1ABL1CDK9
SCHEMBL2127627 0.90 CYP3A4 (0.72) CYP3A4CRBNPDPK1ABL1CDK9
SCHEMBL2127911 0.88 CYP3A4 (0.70) CYP3A4CRBNPDPK1ABL1CDK9
SCHEMBL1542420 0.88 CYP3A4 (0.70) CYP3A4CRBNPDPK1ABL1CDK9
SCHEMBL2128074 0.85 CYP3A4 (1.00) CYP3A4CRBNPDPK1JAK2JAK1
SCHEMBL2128077 0.85 CYP3A4 (1.00) CYP3A4CRBNPDPK1JAK2JAK1
SCHEMBL12675757 0.83 CYP3A4 (0.79) CYP3A4CRBNPDPK1JAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US claimed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US disclosed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP disclosed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885CRBN 1397/4885PDPK1 4145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.